Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 10, 2026. The filing details the outcomes of shareholder votes regarding director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results rather than financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: Three Class II director nominees were elected to serve until the 2029 Annual Meeting:
- Gregory B. Brown, M.D.: 41,373,033 votes for; 1,222,711 abstaining.
- John S. Cochran: 36,914,899 votes for; 5,680,845 abstaining.
- Abigail L. Jenkins: 39,094,166 votes for; 3,501,578 abstaining.
- Executive Compensation: The non-binding advisory proposal to approve executive compensation was approved.
- Votes For: 37,798,609
- Votes Against: 3,192,381
- Votes Abstaining: 1,604,754
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 78,804,323
- Votes Against: 910,690
- Votes Abstaining: 346,313
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting results.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the election of the three Class II members.
- Review the specific executive compensation plan details referenced in the advisory vote.
- Confirm the engagement terms with KPMG LLP for the 2026 fiscal year.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent from this 8-K.